Jazz Pharmaceuticals Shares Edge Higher After Expanded Phase 3 Data Published in NEJM
Jazz Pharmaceuticals shares ticked up in after-hours trading after the New England Journal of Medicine published expanded Phase 3 data from the HERIZON-GEA-01 study. The trial found zanidatamab-containing regimens significantly improved progression-free survival compared with trastuzumab plus chemotherapy, and one zanidatamab combination produced a…